hsc4 cell line (Eppendorf AG)
Eppendorf AG is a verified supplier 
90
Structured Review
Eppendorf AG
hsc4 cell line
Hsc4 Cell Line, supplied by Eppendorf AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hsc4+cell+line/hsc4+cell+line/pmc11473424-45-1-32
Average 90 stars, based on 1 article reviews
Hsc4 Cell Line, supplied by Eppendorf AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/hsc4+cell+line/hsc4+cell+line/pmc11473424-45-1-32
Average 90 stars, based on 1 article reviews
hsc4 cell line - by Bioz Stars,
2026-10
90/100 stars
Images
1) Product Images from "Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC"
Article Title: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC
Journal: Frontiers in Oncology
doi: 10.3389/fonc.2024.1460150
Figure Legend Snippet: Treatment scheme of HNSCC cell lines. HPV-negative (HSC4, Cal-33) and HPV-positive (UM-SCC-47, UD-SCC-2) HNSCC cells were seeded on day 1 and treated with 1µM AZD0156 or 0,1 µM VE-822 24 hours later. Irradiation with 5 Gy was performed 3 hours after treatment with smKI and repeated 24 hours later. Cells were harvested and analyzed 24 hours after the last treatment.
Techniques Used: Irradiation
Figure Legend Snippet: Cell death analysis of HNSCC treated with ATMi or ATRi w/o 2x5Gy RT. RT combined with ATRi shows the highest toxicity in HNSCC cells, regardless of the HPV status. 48 hours post-RT, HPV-negative HSC4 (A) and Cal-33 (B) cells as well as HPV-positive UM-SCC-47 (C) and UD-SCC-2 (D) cells were identified as viable (AnnexinV-, PI-), apoptotic (AnnexinV+, PI-) or necrotic (AnnexinV+, PI+). Percentages of viable, apoptotic, and necrotic cells are shown as stacked bars representing the mean ± SD. A one-tailed Mann-Whitney U test was performed to compare the different treatment approaches within one cell line: *p ≤ 0.05, n=4.
Techniques Used: One-tailed Test, MANN-WHITNEY
Figure Legend Snippet: Flow cytometric analysis of immune checkpoint surface marker on HNSCC after ATMi or ATRi w/o 2x5Gy RT. Combining RT with ATRi leads to the upregulation of immunostimulatory ICOS-L and CD137-L on HNSCC cells, irrespective of the HPV status. 48 hours after the last treatment, the HNSCC cells were harvested and the expression of immunostimulatory ICMs ICOS-L and CD137-L was examined by flow cytometry. The gating strategy is presented in (A) ICM expression is presented as ΔMFI (delta of mean fluorescence intensity of stained samples – background fluorescence) (B, C) . The combined treatment of RT and ATRi increased ICOS-L expression in all four cell lines compared to ATRi or RT alone, as well as in comparison to RT combined with ATMi (B) . Dual treatment with RT and ATMi tended to even decrease ICOS-L surface expression compared to RT or RT with ATRi (B) . RT and ATRi led to enhanced expression of immunostimulatory CD137-L in HPV-negative HSC4 cells compared to ATRi or RT alone, or the combined treatment of RT and ATMi (C) . In HPV-positive UM-SCC-47 and UD-SCC-2 cells, the combination of RT and ATRi also demonstrated higher surface expression of CD137-L compared to RT alone or treatment with RT and ATMi, respectively (C) . A one-tailed Mann-Whitney U test was performed to compare the different treatment approaches within one cell line: *p ≤ 0.05, n=4.
Techniques Used: Marker, Expressing, Flow Cytometry, Fluorescence, Staining, Comparison, One-tailed Test, MANN-WHITNEY
Related Articles
Irradiation:Article Title: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC Article Snippet: Two Article Title: Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib Article Snippet: SBLF8 and SBLF9 were derived from healthy donors, while Cal33 (CVCL_1108), HSC4 (CVCL_1289), UD-SCC-2 (CVCL_E325) and UM-SCC-47 (CVCL_7759) were obtained from Dr. Thorsten Rieckmann (University of Medical Centre Hamburg-Eppendorf, Germany); CLS-354 (Cytion Catalog Number 300152), Detroit 562 (300399) and RPMI2650 (300323) were obtained from Cytion (formerly CLS, Eppelheim, Germany). One-tailed Test:Article Title: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC Article Snippet: Two Article Title: Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib Article Snippet: SBLF8 and SBLF9 were derived from healthy donors, while Cal33 (CVCL_1108), HSC4 (CVCL_1289), UD-SCC-2 (CVCL_E325) and UM-SCC-47 (CVCL_7759) were obtained from Dr. Thorsten Rieckmann (University of Medical Centre Hamburg-Eppendorf, Germany); CLS-354 (Cytion Catalog Number 300152), Detroit 562 (300399) and RPMI2650 (300323) were obtained from Cytion (formerly CLS, Eppelheim, Germany). MANN-WHITNEY:Article Title: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC Article Snippet: Two Article Title: Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib Article Snippet: SBLF8 and SBLF9 were derived from healthy donors, while Cal33 (CVCL_1108), HSC4 (CVCL_1289), UD-SCC-2 (CVCL_E325) and UM-SCC-47 (CVCL_7759) were obtained from Dr. Thorsten Rieckmann (University of Medical Centre Hamburg-Eppendorf, Germany); CLS-354 (Cytion Catalog Number 300152), Detroit 562 (300399) and RPMI2650 (300323) were obtained from Cytion (formerly CLS, Eppelheim, Germany). Marker:Article Title: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC Article Snippet: Two Article Title: Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib Article Snippet: SBLF8 and SBLF9 were derived from healthy donors, while Cal33 (CVCL_1108), HSC4 (CVCL_1289), UD-SCC-2 (CVCL_E325) and UM-SCC-47 (CVCL_7759) were obtained from Dr. Thorsten Rieckmann (University of Medical Centre Hamburg-Eppendorf, Germany); CLS-354 (Cytion Catalog Number 300152), Detroit 562 (300399) and RPMI2650 (300323) were obtained from Cytion (formerly CLS, Eppelheim, Germany). Expressing:Article Title: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC Article Snippet: Two Article Title: Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib Article Snippet: SBLF8 and SBLF9 were derived from healthy donors, while Cal33 (CVCL_1108), HSC4 (CVCL_1289), UD-SCC-2 (CVCL_E325) and UM-SCC-47 (CVCL_7759) were obtained from Dr. Thorsten Rieckmann (University of Medical Centre Hamburg-Eppendorf, Germany); CLS-354 (Cytion Catalog Number 300152), Detroit 562 (300399) and RPMI2650 (300323) were obtained from Cytion (formerly CLS, Eppelheim, Germany). Flow Cytometry:Article Title: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC Article Snippet: Two Article Title: Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib Article Snippet: SBLF8 and SBLF9 were derived from healthy donors, while Cal33 (CVCL_1108), HSC4 (CVCL_1289), UD-SCC-2 (CVCL_E325) and UM-SCC-47 (CVCL_7759) were obtained from Dr. Thorsten Rieckmann (University of Medical Centre Hamburg-Eppendorf, Germany); CLS-354 (Cytion Catalog Number 300152), Detroit 562 (300399) and RPMI2650 (300323) were obtained from Cytion (formerly CLS, Eppelheim, Germany). Fluorescence:Article Title: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC Article Snippet: Two Article Title: Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib Article Snippet: SBLF8 and SBLF9 were derived from healthy donors, while Cal33 (CVCL_1108), HSC4 (CVCL_1289), UD-SCC-2 (CVCL_E325) and UM-SCC-47 (CVCL_7759) were obtained from Dr. Thorsten Rieckmann (University of Medical Centre Hamburg-Eppendorf, Germany); CLS-354 (Cytion Catalog Number 300152), Detroit 562 (300399) and RPMI2650 (300323) were obtained from Cytion (formerly CLS, Eppelheim, Germany). Staining:Article Title: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC Article Snippet: Two Article Title: Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib Article Snippet: SBLF8 and SBLF9 were derived from healthy donors, while Cal33 (CVCL_1108), HSC4 (CVCL_1289), UD-SCC-2 (CVCL_E325) and UM-SCC-47 (CVCL_7759) were obtained from Dr. Thorsten Rieckmann (University of Medical Centre Hamburg-Eppendorf, Germany); CLS-354 (Cytion Catalog Number 300152), Detroit 562 (300399) and RPMI2650 (300323) were obtained from Cytion (formerly CLS, Eppelheim, Germany). Comparison:Article Title: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC Article Snippet: Two Article Title: Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib Article Snippet: SBLF8 and SBLF9 were derived from healthy donors, while Cal33 (CVCL_1108), HSC4 (CVCL_1289), UD-SCC-2 (CVCL_E325) and UM-SCC-47 (CVCL_7759) were obtained from Dr. Thorsten Rieckmann (University of Medical Centre Hamburg-Eppendorf, Germany); CLS-354 (Cytion Catalog Number 300152), Detroit 562 (300399) and RPMI2650 (300323) were obtained from Cytion (formerly CLS, Eppelheim, Germany). Derivative Assay:Article Title: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC Article Snippet: Two Article Title: Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib Article Snippet: SBLF8 and SBLF9 were derived from healthy donors, while Cal33 (CVCL_1108), HSC4 (CVCL_1289), UD-SCC-2 (CVCL_E325) and UM-SCC-47 (CVCL_7759) were obtained from Dr. Thorsten Rieckmann (University of Medical Centre Hamburg-Eppendorf, Germany); CLS-354 (Cytion Catalog Number 300152), Detroit 562 (300399) and RPMI2650 (300323) were obtained from Cytion (formerly CLS, Eppelheim, Germany). Colony Assay:Article Title: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC Article Snippet: Two Article Title: Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib Article Snippet: SBLF8 and SBLF9 were derived from healthy donors, while Cal33 (CVCL_1108), HSC4 (CVCL_1289), UD-SCC-2 (CVCL_E325) and UM-SCC-47 (CVCL_7759) were obtained from Dr. Thorsten Rieckmann (University of Medical Centre Hamburg-Eppendorf, Germany); CLS-354 (Cytion Catalog Number 300152), Detroit 562 (300399) and RPMI2650 (300323) were obtained from Cytion (formerly CLS, Eppelheim, Germany). Control:Article Title: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC Article Snippet: Two Article Title: Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib Article Snippet: SBLF8 and SBLF9 were derived from healthy donors, while Cal33 (CVCL_1108), HSC4 (CVCL_1289), UD-SCC-2 (CVCL_E325) and UM-SCC-47 (CVCL_7759) were obtained from Dr. Thorsten Rieckmann (University of Medical Centre Hamburg-Eppendorf, Germany); CLS-354 (Cytion Catalog Number 300152), Detroit 562 (300399) and RPMI2650 (300323) were obtained from Cytion (formerly CLS, Eppelheim, Germany). Two Tailed Test:Article Title: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC Article Snippet: Two Article Title: Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib Article Snippet: SBLF8 and SBLF9 were derived from healthy donors, while Cal33 (CVCL_1108), HSC4 (CVCL_1289), UD-SCC-2 (CVCL_E325) and UM-SCC-47 (CVCL_7759) were obtained from Dr. Thorsten Rieckmann (University of Medical Centre Hamburg-Eppendorf, Germany); CLS-354 (Cytion Catalog Number 300152), Detroit 562 (300399) and RPMI2650 (300323) were obtained from Cytion (formerly CLS, Eppelheim, Germany). Incubation:Article Title: Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC Article Snippet: Two Article Title: Effective Radiosensitization of HNSCC Cell Lines by DNA-PKcs Inhibitor AZD7648 and PARP Inhibitors Talazoparib and Niraparib Article Snippet: SBLF8 and SBLF9 were derived from healthy donors, while Cal33 (CVCL_1108), HSC4 (CVCL_1289), UD-SCC-2 (CVCL_E325) and UM-SCC-47 (CVCL_7759) were obtained from Dr. Thorsten Rieckmann (University of Medical Centre Hamburg-Eppendorf, Germany); CLS-354 (Cytion Catalog Number 300152), Detroit 562 (300399) and RPMI2650 (300323) were obtained from Cytion (formerly CLS, Eppelheim, Germany). |
